Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29588295 | 0.86 | RAB9A (0.55) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL10671645 | 0.84 | CTSD (0.53) | HPGDALDH1A1NPC1RAB9ACTSD | |
| SCHEMBL28150235 | 0.83 | IRAK4 (0.45) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL31318924 | 0.83 | CTSD (0.55) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL4303504 | 0.83 | CTSD (0.55) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL31257134 | 0.83 | CTSD (0.55) | KMT2AHPGDALDH1A1HTTNPC1 | |
| 1,2-Dimethoxybenzene SCHEMBL27707733 | 0.83 | KMT2A (0.69) | KMT2AHPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL8523805 | 0.81 | HPGD (0.49) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL9344621 | 0.80 | MAPT (0.49) | KMT2AHPGDALDH1A1HTTNPC1 | |
| SCHEMBL2339959 | 0.80 | CTSD (0.51) | KMT2AHPGDALDH1A1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1029932-C | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH INC (US) | 1995-10-11 | — | — | CN | claimed |
| CN-1060770-A | The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor | BIORESEARCH INC (US) | 1992-05-06 | — | — | CN | claimed |
| EP-3268374-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC AG (DE) | 2018-01-17 | — | — | EP | disclosed |
| CN-107548396-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-107548397-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| WO-2016146583-A1 | KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION | 4SC DISCOVERY GMBH (DE) | 2016-09-22 | — | — | WO | disclosed |
| CN-102060692-A | Preparation method of gamma-(p-methoxyphenyl) butyric acid | HUNAN TIANCHENG PHARMACEUTICAL COMPANY LTD | 2011-05-18 | — | — | CN | disclosed |
| US-6602895-B2 | Inhibitors of factor Xa with a neutral P1 specificity group | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | GALEMMO ROBERT A (US) | 2003-05-15 | — | — | US | disclosed |
| US-6403620-B1 | ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-11 | — | — | US | disclosed |
| EP-0991625-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 2000-04-12 | — | — | EP | disclosed |
| US-5998424-A | ANTICOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998057937-A2 | INHIBITORS OF FACTOR XA WITH A NEUTRAL P1 SPECIFICITY GROUP | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
| CN-1141627-A | Indole derivatives for the treatment of estrogen-related tumors and diseases | MERRELL DOW PHARMA (US) | 1997-01-29 | — | — | CN | disclosed |
| CN-1029932-C | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers | BIORESEARCH INC (US) | 1995-10-11 | — | — | CN | disclosed |
| CN-1060770-A | The sweetness inhibitor that contains substantially tasteless is as bitter inhibitor or contain the absorbed thing of the bitter inhibitor of substantially tasteless as sweetness inhibitor | BIORESEARCH INC (US) | 1992-05-06 | — | — | CN | disclosed |
| EP-0156317-A2 | Foodstuffs containing sweetness inhibiting agents and process for inhibiting the sweetness perception of a foodstuff | GENERAL FOODS CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092740-A1 | Inhibitors of factor Xa with a neutral P1 specificity group | F12, F11, SERPINC1 | KMT2A 4193/4885HPGD 1756/4885ALDH1A1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.